€0.32
Your prediction
Financial data and news for Recce Pharmaceuticals Ltd.
sharewise wants to provide you with the best news and tools for Recce Pharmaceuticals Ltd., so we directly link to the best financial data sources.
Financials
News
Positive Efficacy Data of Inhaled RECCE® 327 in Hospital/Ventilator-Acquired Pneumonia (HAP/VAP) in Mice Models
Highlights:
- RECCE® 327 (R327) demonstrated significant antibacterial activity against multidrug-resistant Acinetobacter baumannii (A. baumannii), one of the most challenging
RECCE® 327 Topical Gel Highly Effective and Accelerated Wound Healing for Burn Wounds in Rat Infection Models
Highlights:
- RECCE® 327 Topical Gel (R327G) highly effective against Methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa infected burn wounds (in-vivo)
-
Hong Kong Patent Granted for RECCE® Anti-Infectives
Sydney Australia, 27 November 2025: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) a leading developer of a New Class of Synthetic Anti-Infectives, is pleased to
Patient Dosing and Multiple Sites Activated in Registrational Phase 3 Clinical Trial for Diabetic Foot Infections in Indonesia
Highlights:
- Patient dosing is underway for Registrational Phase 3 Clinical Trial for Diabetic Foot Infections (DFI), with five (5) clinical study sites now activated across one